Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study.

El Kababji S, Mitsakakis N, Jonker E, Beltran-Bless AA, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow W, Gralow J, Savard MF, Fesl C, Hlauschek D, Balic M, Rinnerthaler G, Greil R, Gnant M, Clemons M, El Emam K. J Med Internet Res. 2025 Mar 5;27:e66821. doi: 10.2196/66821. PMID: 40053790.

A comparison of breast cancer incidence and cancer stages before and after the introduction of the Austrian national breast cancer screening program in the fe-deral state of Salzburg: Real-world data from the Tumor Registry Salzburg.

Gampenrieder SP, Vaisband M, Rinnerthaler G, Weiss L, Jaud B, Sprenger M, Greil R. Wien Klin Wochenschr. 2025 Apr 1. doi: 10.1007/s00508-025-02508-8. Online ahead of print. PMID: 40167619.

A comparison of breast cancer incidence and cancer stages before and after the introduction of the Austrian national breast cancer screening program in the federal state of Salzburg: Real-world data from the Tumor Registry Salzburg.

Gampenrieder SP, Vaisband M, Rinnerthaler G, Weiss L, Jaud B, Sprenger M, Greil R. Wien Klin Wochenschr. 2025 Apr 1. doi: 10.1007/s00508-025-02508-8. Online ahead of print. PMID: 40167619.

Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials.

Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer CF, Halper S, Steger G, Suppan C, Gampenrieder SP, Helfgott R, Egle D, Filipits M, Jakesz R, Sölkner L, Fesl C, Gnant M, Fitzal F; Austrian Breast & Colorectal Cancer Study Group. Breast. 2025 Apr;80:104415. doi: 10.1016/j.breast.2025.104415. Epub 2025 Feb 19.PMID: 39985843 Free PMC article. Clinical Trial.

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.

Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, Tedeschi A, Owen C, Skarbnik A, Lysak D, Eom KS, Šimkovič M, Pavlovsky MA, Kater AP, Eichhorst B, Miller K, Munugalavadla V, Yu T, de Borja M, Ghia P; AMPLIFY investigators; AMPLIFY Investigators. N Engl J Med. 2025 Feb 20;392(8):748-762. doi: 10.1056/NEJMoa2409804. E-pub 2025 Feb 5.PMID: 39976417 Clinical Trial.

Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.

Rinnerthaler G, Egle D, Bartsch R, Schmitt CA, Petzer A, Balic M, Petru E, Denison U, Sin-ger CF, Bjelic-Radisic V, Gampenrieder SP, Knauer M, Sotlar K, Brunner C, Posch F, Hlauschek D, Sölkner L, Bago-Horvath Z, Filipits M, Gili M, Ritter M, Wieser V, Albertini C, Zaborsky N, Weiss L, Marhold M, Schneeweiss B, Pusch R, Gnant M, Greil R. Nat Cancer. 2025 Jan;6(1):41-50. doi: 10.1038/s43018-024-00890-2. Epub 2025 Jan 16. PMID: 39820125 Free PMC article. Clinical Trial.

HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd.

Singer CF, Jahn SW, Hlauschek D, Heber UM, Mang-Manger C, Egle D, Balic M, Pichler A, Pfeiler G, Kacerovsky-Strobl S, Suppan C, Ritter M, Petru E, Greil R, Bago-Horvath Z, Deutschmann C, Steger GG, Seifert M, Fitzal F, Bartsch R, Santhanagopal A, Machacek-Link J, Sellami D, Schwarz M, Fesl C, Sölkner L, Esker S, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group. Cancer Commun (Lond). 2025 Jan 6. doi: 10.1002/cac2.12657. Online ahead of print. PMID: 39757921 No abstract available.

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.

Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Šimkovič M, Österborg A, Laurenti L, Walker PA, Opat SS, Ciepluch H, Greil R, Hanna M, Tani M, Trněný M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, de Guibert S, Tumyan G, Laribi K, García-Marco JA, Li JY, Tian T, Liu Y, Korol-kiewicz R, Szeto A, Tam CS, Jurczak W. J Clin Oncol. 2025 Mar;43(7):780-787. doi: 10.1200/JCO-24-02265. Epub 2024 Dec 8.PMID: 39647999 Free PMC article. Clinical Trial.

Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a Phase II study.

Westin JR, Phillips TJ, Mehta A, Hoffmann MS, Gonzalez-Barca E, Thieblemont C, Bastos-Oreiro M, Greil R, Giebel S, Wei MC, Wang J, Bucher R, Sit J, Penuel E, Purev E, Yee DL, Bergua Burgues JM. Blood Adv. 2025 Feb 5:bloodadvances.2024014907. doi: 10.1182/bloodadvances.2024014907. Online ahead of print. PMID: 3990848.

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.

Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, D’Hondt V, Conlin AK, Guarneri V, Wapnir IL, Jackisch C, Arce-Salinas C, Fasching PA, DiGiovanna MP, Crown JP, Wuelfing P, Shao Z, Rota Caremoli E, Bonnefoi HR, Hennessy BT, Stamatovic L, Castro-Salguero H, Brufsky AM, Knott A, Siddiqui A, Lambertini C, Boulet T, Nyawira B, Restuccia E, Loibl S; KATHE-RINE Study Group. N Engl J Med. 2025 Jan 16;392(3):249-257. doi: 10.1056/NEJMoa2406070.PMID: 39813643 Clinical Trial.